Cilo Cybin's Stock Faces Data Inconsistencies Amid Volatile 52‑Week Range Investors are cautioned by a contradictory +100% change on Cilo Cybin's quote page, urging verification with live JSE data as the company's 52‑week price swings between 70.00 and 690.00 ZAR. The South African medical‑cannabis firm remains a small‑cap player with a focused product line, but its market data highlights the importance of cross‑checking real‑time feeds before trading. The latest snapshot of the South African medical‑cannabis specialist Cilo Cybin Ltd. shows a steady 200.00 ZAR share price as of 9 September 2026. At first glance the company's figures paint a picture of a small‑cap venture with a volatile trading history. A 52‑week price swing between 70.00 ZAR and 690.00 ZAR, combined with a current valuation of around 576.18 million ZAR, signals the kind of roller‑coaster behaviour that many investors associate with niche, high‑growth sectors. However, a closer look at the data reveals a glaring inconsistency that may throw off even the most experienced trader. The quote page lists a +100.00 percent change alongside the 200.00 ZAR price, a figure that cannot be reconciled with the previous close of 200.00 ZAR.The discrepancy points to a data feed glitch or a display artefact - a warning for market participants to confirm any trading signals with a live, broker‑level data source before placing orders. Cilo Cybin's profile is unmistakably that of a specialised, small‑cap player in the South African jungle of medical‑cannabis providers. Founded in 2018 in Centurion, the firm cultivates, manufactures and markets a broad roll‑up of medical cannabis products that span CBD and THC distillates, isolates, oils, flower and vapes.Its narrow focus on medical‑grade offerings - as opposed to a diversified pharmaceutical or wellness pipeline - explains much of the wide price volatility. The company's market capitalisation of just over 576 million ZAR keeps it firmly below the large‑cap threshold for the Johannesburg Stock Exchange (JSE), and it features in many technical‑analysis reports as a high‑beta stock. The trading data released by the Investing.com data page should be interpreted with caution.While the single‑day range of 188.00 to 200.00 ZAR suggests a period of relative stability, the example of the +100.00 ZAR and +100.00 percent change is an anomaly that can mislead investors. The technical model that produced the sharp upside figure relies solely on moving averages and other chart‑based constructs, and it offers no direct insight into Cilo Cybin's earnings, growth trajectory or valuation fundamentals.Even the fair‑value metrics reported by the platform are listed as 'N/A', and the stock is not included in any of the AI‑picked investment strategies on the site. Consequently, traders should treat the bullish signal as a potential technical cue rather than a conclusive endorsement of the company's prospects. For anyone looking to trade Cilo Cybin, the 52‑week range remains a useful reference for gauging risk.A current price of 200.00 ZAR lies well below the midpoint of the historic 70.00‑to‑690.00 envelope, suggesting that the share could experience further upside or downside depending on broader market sentiment and the firm's operational performance. Yet, the data page makes it clear that the figures provided are indicative rather than real‑time; they are not to be used as a source for time‑critical limit orders.Those interested in precise trade placement should refer to a live JSE feed or their broker's system to confirm that the price truly stands where the feed indicates and that the purported 100.00 percent jump is an error. By doing so, investors can avoid pitfalls associated with erroneous or out‑of‑date market data and make decisions that reflect the actual health and marketability of Cilo Cybin's stock.In summary, while Cilo Cybin remains an intriguing small‑cap opportunity in the burgeoning medical‑cannabis space, its market data is marred by clear inaccuracies. Traders and researchers alike should cross‑check any anomalous figures against a reliable source, use the wide 52‑week range to understand potential volatility, and recognise that the current 200.00 ZAR price sits on a fundamentally narrow product line that could swing dramatically as the sector matures.By staying vigilant and sticking to verified data, one can mitigate risk and capitalize on the unique growth opportunities the company presents.